ABCL575 is an investigational half-life-extended anti-OX40L monoclonal antibody for moderate-to-severe atopic dermatitis.
ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in atopic dermatitis. It is engineered with a modified Fc domain for Fc-silencing and half-life extension, and preclinical data show potent inhibition of T-cell-mediated inflammatory pathways with an in vivo half-life expected to support less frequent dosing than current clinical-stage molecules.
A Phase 1 trial in healthy participants with subcutaneous doses began in the third quarter of 2025. The program is an internal AbCellera candidate with potential application in other inflammatory and autoimmune conditions.
| Attribute | Abcl575 | Dupixent | Ebglyss | Triv-509 | |
|---|---|---|---|---|---|
| Provider |  |  |  |  | |
| Founded | 2012 | 1973 | 1876 | 2023 | |
| Sells To | Enterprise, Government | Enterprise | Consumers, Enterprise | B2B, Enterprise | |
| Pricing Model | Recurring, Software | Recurring | Recurring, Software, Transactional | Licensing, Pre-Revenue | |
| Ownership | Public | Public | Public | Private, Venture-backed |
Provider
Founded 2012
Sells To Enterprise, Government
Pricing Model Recurring, Software
Ownership Public
Provider
Founded 1973
Sells To Enterprise
Pricing Model Recurring
Ownership Public
Provider
Founded 1876
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public
Provider
Founded 2023
Sells To B2B, Enterprise
Pricing Model Licensing, Pre-Revenue
Ownership Private, Venture-backed
First-in-class once-daily oral small-molecule candidate with a novel non-kinase mechanism in Phase 2a for atopic dermatitis and asthma.
A first-in-class bispecific antibody targeting kallikreins 5 and 7 and interleukin 13, in Phase 1 clinical trials for atopic dermatitis.
Prescription dermatology medicines for moderate-to-severe skin conditions.
First-in-class once-daily oral small-molecule candidate with a novel non-kinase mechanism in Phase 2a for atopic dermatitis and asthma.
A first-in-class bispecific antibody targeting kallikreins 5 and 7 and interleukin 13, in Phase 1 clinical trials for atopic dermatitis.
Prescription dermatology medicines for moderate-to-severe skin conditions.
